Skip to main content

Table 2 Results of the evaluation of osteoclastogenesis

From: The effect of genetically modified platelet-derived growth factor-BB over-expressing mesenchymal stromal cells during core decompression for steroid-associated osteonecrosis of the femoral head in rabbits

Average osteoclast density (#/mm2) by position in femoral head (SD)
  Subchondral bone
1 2 3 4 Total P value
CD 13.9 (5.9) 14.0 (4.4) 10.2 (1.9) 10.4 (7.2) 12.1 (5.2) 0.361
HG 16.4 (9.5) 10.0 (5.5) 11.7 (3.0) 9.2 (7.7) 11.8 (7.0) 0.298
MSC 15.0 (6.4) 14.8 (7.0) 16.2 (12.4) 9.1 (2.7) 13.8 (7.9) 0.816
PGK-PDGF-BB-MSC 13.7 (3.8) 14.2 (6.6) 16.5 (7.7) 12.9 (7.3) 14.3 (6.2) 1.0
  Surrounding tunnel
5 6 7 Total P value
CD 10.7 (4.1) 5.6 (4.8) 13.4 (6.0) 9.8 (5.8)  < 0.05
HG 9.9 (12.5) 4.9 (4.8) 4.0 (3.0) 6.3 (7.9)  < 0.001
MSC 10.6 (4.5) 6.9 (4.1) 7.8 (5.3) 8.4 (4.7)  < 0.01
PGK-PDGF-BB-MSC 17.5 (8.2) 13.7 (8.6) 17.8 (14.6) 16.4 (10.4) 1.0
  1. The average osteoclast density for each position in the femoral head as described in Fig. 1 was calculated for each treatment group. The average osteoclast density for each region in the femoral head was calculated for each treatment group. A mixed effects model, where treatment group and femoral head position served as fixed effects, was used to perform the statistical analysis. The P values shown correspond to comparisons with the PGK-PDGF-BB-MSC treatment group. Comparisons between all other treatment groups did not reach statistical significance. SD standard deviation, CD core decompression, HG hydrogel, MSC mesenchymal stromal cell, PGK-PDGF-BB-MSC genetically modified phosphoglycerate kinase promoter platelet-derived growth factor-BB over-expressing MSC